AUTHOR INFORMATION PACK
TABLE OF CONTENTS
COMMUNITY ONCOLOGY is an independent, peer-reviewed journal that features articles relating to research, quality of care, and practice management issues in the community setting. The Journal reaches more than 26,000 physicians, physician assistants, nurses, nurse practitioners, pharmacists, and administrators each month and has become a vital clinical forum and resource in the COMMUNITY ONCOLOGY practice setting.
EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus
David H. Henry, MD, FACP, Pennsylvania Hospital, Philadelphia
Jame Abraham, MD, West Virginia University, Morgantown
Linda D. Bosserman, MD, FACP, Wilshire Oncology Medical Group, La Verne, California
Debra A. Patt, MD, MPH, Texas Oncology, Austin
Athanassios Argiris, MD, University of Texas Health Science Center, San Antonio, Texas
Lodovico Balducci, MD, Moffitt Cancer Center & Research Institute, Tampa, Florida
Johanna Bendell, MD, Sarah Cannon Research Institute, Nashville, Tennessee
Charles L. Bennett, MD, PhD, MPP, University of South Carolina, Columbia
Roy A. Beveridge, MD, US Oncology, Houston, Texas
Ralph V. Boccia, MD, Georgetown University, Washington, DC
Matt Brow, US Oncology, Washington, DC
Leslie Busby, MD, Rocky Mountain Cancer Centers, Boulder, Colorado
Sant P. Chawla, MD, FRACP, Sarcoma Oncology Center, Santa Monica, California
Corey J. Langer, MD, University of Pennsylvania, Philadelphia
Michael J. Fisch, MD, MPH, University of Texas MD Anderson Cancer Center, Houston
John A. Fracchia, MD, Lenox Hill Hospital, New York
James N. George, MD, University of Oklahoma Health Sciences Center, Oklahoma City
James Gilmore, PharmD, Georgia Cancer Specialists, Atlanta
Axel Grothey, MD, Mayo Clinic, Rochester, Minnesota
Daniel G. Haller, MD, Professor emeritus, University of Pennsylvania, Bryn Mawr
David M.J. Hoffman, MD, Tower Hematology Oncology Medical Group, Beverly Hills, California
Jimmie Holland, MD, Memorial Sloan-Kettering Cancer Center, New York
Thomas B. Julian, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania
Vivek S. Kavadi, MD, Texas Oncology, Austin
Kartik Konduri, MD, Texas Oncology, Austin
Shaji Kumar, MD, Mayo Clinic, Rochester, Minnesota
Leslie Rodgers Laufman, MD, Blood and Cancer Care of Ohio, Columbus
Stuart M. Lichtman, MD, Memorial Sloan-Kettering Cancer Center, Commack, New York
John L. Marshall, MD, Lombardi Comprehensive Cancer Center, Washington, DC
Cathy Maxwell, RN, OCN, CCRC, Advanced Medical Specialties, LLC, Miami, Florida
Bradley J. Monk, MD, FACOG, Creighton University School of Medicine and St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
Anne Moore, MD, Weill Medical College of Cornell University, New York
Eric Nadler, MD, Texas Oncology, Austin
Marcus Neubauer, MD, Kansas City Cancer Centers, Overland Park, Kansas
Deborah A. Nagle, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Geoffrey R. Norman, PhD, McMaster University, Hamilton, Ontario, Canada
Steven O’Day, MD, The Angeles Clinic and Research Institute, Los Angeles, California
Theodore A. Okon, MBA, Supportive Oncology Services, Memphis, Tennessee
Philip A. Philip, MD, PhD, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Jondavid Pollock, MD, PhD, Schiffler Cancer Center, Wheeling, West Virginia
Nicholas J. Robert, MD, US Oncology, Fairfax, Virginia
Peter J. Rosen, MD, Roy and Patricia Disney Family Cancer Research Center, Burbank, California
Myrna R. Rosenfeld, MD, PhD, University of PennsylvaniaSchool of Medicine, Philadelphia
Lee S. Schwartzberg, MD, FACP, The West Clinic, Memphis, Tennessee
Mark A. Sitarik, MD, Rocky Mountain Cancer Centers, Boulder, Colorado
David Streiner, PhD, CPsych, University of Toronto, Ontario, Canada
Debu Tripathy, MD, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles
Steven Tucker, MD, Tucker Medical, Singapore, Malaysia
COMMUNITY ONCOLOGY publishes peer-reviewed articles and commentary on all aspects of clinical oncology practice and evidence-based practices for caring for patients with cancer.
Please note the following:
TYPES OF ARTICLES
Article types include original research reports of clinical studies in practice-based settings; review and state-of-the-art papers; commentaries; and letters to the editor. Case letters and case reports will be considered as letters to the editor.
Below is a summary of the categories of papers for COMMUNITY ONCOLOGY .
Original Research Reports
These are reports on randomized trials, intervention studies, cohort studies, case-control studies, epidemiologic assessments, other observational studies, surveys, cost-effectiveness analyses, and studies of screening and diagnostic tests.
Original research reports will:
Review and State-of-the-Art Papers
The editors will consider invited and uninvited review papers. These manuscripts gather and summarize information from current literature and data sources on clinical topics. They should do the following:
Review articles are often used as guides in the practice setting, and therefore they must be systematic, must include relevant data, and must not be influenced by the authors’ opinions or biases (AMA 1.2).
The search and selection processes for research sources, such as databases, should be described in the manuscript. The research sources should be as current as possible, preferably with the search having been conducted within a few months of submission. Authors should detail in their cover letters how their review differs from existing reviews on the subject.
Review and state-of-the-art manuscripts will:
Succinct opinion pieces will also be considered. These can address any current topic that has a bearing on community-based clinical practice: research findings, health policy and/or law, ethics, practice trends, or practice economics. The arguments should be focused and succinctly presented.
A commentary will:
Letters to the Editor
Letters to the editor should focus on a specific article that has been published in COMMUNITY ONCOLOGY .
A letter to the editor will:
Letters will be sent for response to the authors of the original article. This response may be published or sent directly to the commentator at the discretion of the editor. Letters will be published at the discretion of the editors, and are subject to abridgement and editing for style and content. Questions or comments that could be addressed directly to authors of the original article (including complaints about missed citations) should be sent directly to those authors.
These brief reports usually describe a step-by-step approach to clinical decision making in the diagnosis and treatment of a patient who has an unusual or complicated presentation or diagnosis.
A case letter will:
New or preliminary research findings may be considered for publication as research letters.
A research letter will:
BEFORE YOU BEGIN
Ethics in Publishing
Studies should be in compliance with human studies committees of the authors' institution(s) and US Food and Drug Administration guidelines.
Studies must be performed with the subjects' written informed consent. Authors must provide the details of this procedure and indicate that the institutional committee on human research has approved the study protocol. If radiation is used in a research procedure, the radiation exposure must be specified in the Methods section.
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. Patients have a right to privacy. Therefore, identifying information – including patients' images, names, initials, or hospital numbers – should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). Written consents must be provided to the editorial office on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning, and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Conflict of Interest
COMMUNITY ONCOLOGY requires all authors to acknowledge, in the comments section of EM (http://www.editorialmanager.com/co/default.asp), all funding sources that supported their work, as well as all institutional or corporate affiliations of the authors. The title page must also include a publishable statement disclosing any associations (current and over the past 5 years) that might pose a conflict of interest. These include but are not limited to employment; royalties; consultant arrangements with a commercial entity; stock or other equity ownership; stock options; patent licensing arrangements; payments for conducting or publicizing a product or study; or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated in the publishable disclosure statement. If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, authors should list them in the comments section of EM (http://www.editorialmanager.com/co/default.asp). They should also explain these interests as well as the reason for the need for confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests or conflicts of interest that might interfere with objectivity (or to recuse him- or herself from acting as a reviewer). The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions, to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.
Submission of an article implies that the work described has not been previously published (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.
Each author must have contributed significantly to the submitted work. If there are more than four authors, the contribution of each must be substantiated in the cover letter. If authorship is attributed to a group (either solely or in addition to one or more individual authors), then all members of the group must meet the full criteria and requirements for authorship. To save space, if group members have been listed in COMMUNITY ONCOLOGY , the article should be referenced rather than reprinting the list.
The editors consider authorship to include all of the following:
Participation solely in the collection of data does not justify authorship but may be appropriately acknowledged in the Acknowledgment section.
Manuscripts must be submitted with a cover letter that includes the following:
Changes to Authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
Upon acceptance of an article, authors will be asked to complete a “Journal Publishing Agreement. Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. There are preprinted forms for use by authors in these cases.
Retained Author Rights
As an author, you (or your employer or institution) retain certain rights; for details, please refer to www.editorialmanager.com/co/default.asp.
Role of the Funding Source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article, and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
If the funding source(s) had no such involvement, then this should be stated.
PREPARING YOUR MANUSCRIPT
It is important that the file be saved in the native format of the word processing program used. Microsoft Word documents are preferable.
Text Formatting: Simplicity!
Please DO format the text as follows:
DO NOT use the following in your manuscripts:
Title Page. Please include the following elements on the title page. Begin numbering the pages of the manuscript with the title page as page 1.
Manuscript title. The title should be no longer than 15 words. Follow AMA 2.1 guidelines.
Author bylines. Please note the following:
Author affiliations. Follow AMA 2.3.3, with these 2 exceptions:
Corresponding author. See AMA 2.10.4 for guidance and samples. The corresponding author must inform the Managing Editor of any changes in contact information.
Abstract. Original research reports and review articles require concise, factual structured or unstructured abstracts. Follow AMA 2.5 guidelines, with the following requirements that are specific to COMMUNITY ONCOLOGY :
An abstract is often presented separately from the article; thus it must be able to stand alone, so references in the abstract should be avoided. If a reference is essential, then the reference should be given in full. Likewise, all abbreviations must be defined at first mention in the abstract, even if they are also defined in the article’s main body.
Keywords. Immediately after the abstract, provide a maximum of 6 keywords. These keywords will be used for indexing purposes. See AMA 2.6 for guidance. In addition:
Main Body of Running Text
Introduction. The introduction should be 2-3 paragraphs long. It should state the objectives of the work and provide an adequate background and context for the article. It should not include a detailed literature survey or a summary of the results.
Methods. This section should describe study design; the topic that is being studied; details about the participants; inclusion and exclusion criteria; interventions; outcome measures and observations; and a statistical analysis. It should provide sufficient detail to allow the work to be reproduced. Methods that have already been published should be indicated by a reference; only relevant modifications should be described. See AMA 2.8 for guidance.
Results. Results should be clear, concise, and specific to the research hypothesis. See AMA 2.8 for guidance.
Discussion. This section should explore the significance of the results of the work; do not repeat the results. Avoid extensive citations and discussion of published literature. Instead, address the research hypothesis, and compare your findings with those of similar studies. Also, discuss generalizability of results, study limitations, unexpected findings (and possible explanations for them), and suggested future studies. The final sentence or two of the discussion section should be reserved for your conclusions.
Please refer to AMA 2.10 for guidance. Collate acknowledgments on the title page, with the author(s) and corresponding author’s information so that the information is not included in the version of the manuscript that is sent out for blind review. List here those individuals who provided help during the research (eg, writing, or editorial or statistical assistance). After the manuscript has been accepted for publication, the editor will place the Acknowledgments information in a separate section at the end of the article before the references.
Please consult AMA chapter 3 for a comprehensive guide to reference styles, including samples. Manuscripts that do not follow AMA guidelines will be returned to the author(s) for revision.
In the running text, please note the following:
In the reference list, please format author names according to AMA 3.7 and 3.8:
In the reference list, please format other citation information as follows:
COMMUNITY ONCOLOGY generally does not publish appendices.
Figures, Tables, and Electronic Artwork
These features should supplement—not reiterate—data and article content. They should provide the reader with easy, at-a-glance access to accurate, succinctly presented data or information.
All visual elements should be numbered according to their order of reference in the text. The text citation should be (Table 3) or (Figure 2).
Tables. Tables present data and information that support—but do not reiterate—statements in the running text. Accuracy, clarity, and logical data presentation are of paramount importance in tables. Follow AMA 4.1 for guidance and samples. Specific requirements for COMMUNITY ONCOLOGY include the following:
Footnotes: Place table footnotes below the table body, and indicate them with superscript lowercase letters that correspond to the citation in the table body as follows:
a The phase II studies reported treatment-related adverse events; the phase III study reported treatment-emergent adverse events. b This was a comparative effectiveness trial of axitinib versus sorafenib.
Figures. Graphs, maps, illustrations, algorithms, computer-generated images, and photographs are all designated as figures. In general, follow the guidelines and samples in AMA 4.2.
Specific requirements for COMMUNITY ONCOLOGY include the following:
Note: We cannot accept images that are optimized for screen use (eg, in BMP, PICT, or WPG) because their resolution will be too low.
Define abbreviations that are not standard on the first page of the article. Ensure consistency of abbreviations throughout the article. In the abstract, unavoidable abbreviations must be defined at their first mention as well.
Follow internationally accepted rules and conventions, and use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.
COMMUNITY ONCOLOGY does not use footnotes. Please incorporate any explanatory material into the text.
COMMUNITY ONCOLOGY video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. As with a figure or table, refer to the video or animation content and noting in the body text where it should be placed.
All submitted files should be properly labeled so that they directly relate to the video file's content. To ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats, with a preferred maximum size of 50 MB.
Video and animation files will be published online in the electronic version of your article. Please supply, good quality original still images with your files; you can choose any frame from the video or animation, or make a separate image. These will be used instead of standard icons, and will personalize the link to your video data.
Note: Because video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
COMMUNITY ONCOLOGY accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips, and more. Supplementary files will be published online alongside the electronic version of your article on the Journal’s site, www.oncologypractice.com/communityoncology/.
To ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file..
SUBMITTING YOUR MANUSCRIPT
Online Submission of Source Files All COMMUNITY ONCOLOGY manuscripts must be submitted online through EMEditorialManager (EM), a Web-based electronic submission platform.
The website is www.editorialmanager.com/co/.
All tracking and follow-up will be done through the EM. The site also provides instructions for manuscript submission and a tutorial for authors www.editorialmanager.com/homepage/docs/Author_Tutorial.pdf.
Required Submission Materials
All manuscript submissions must include the following forms:
These forms can be downloaded from XXX.
Please scan the completed forms and upload them to the EM with your submission. Problems? Contact Renée Matthews at email@example.com.
With the manuscript, authors may submit the names, addresses, and e-mail addresses of three reviewers. Note: The editor retains the sole right to decide whether or not the suggested reviewers are used.
The EM automatically converts your manuscript source files to a single PDF file of the article, which is used in the peer-review process. However, these source files are needed for processing after acceptance. This is why it’s important that you adhere to the AMA style guidelines outlined in the “Preparation of Your Manuscript” section of these guidelines.
All correspondence—including notification of the editor's decision and requests for revision—takes place by e-mail. There is no paper trail. You can reach Renée Matthews at firstname.lastname@example.org.
Before you upload your manuscript to the EM for review, please check the following:
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly “articles in press,” because they have not yet received their full bibliographic information.
When editors use the DOI to create URL hyperlinks to documents on the Web, the DOIs are guaranteed never to change.
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address, then paper proofs will be sent by post), or a link will be provided in the e-mail so that authors can download the files themselves.
We now provides authors with PDF proofs that can be annotated. To access these, you will need to download Adobe Reader version 7 (or higher), which is available free from get.adobe.com/reader. To annotate the PDF, you will also need to make a copy of the PDF you receive and save it to your desktop. The PDF you receive serves as the parent file and cannot be changed, only copies of the parent can be changed.) Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site (http://www.adobe.com/products/reader/tech-specs.html).
PLEASE RETURN THE PROOFED PDF TO THE MANAGER EDITOR, RENEE MATTHEWS (email@example.com) WITHIN 48 HOURS OF THEIR RECEIPT.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to firstname.lastname@example.org in an e-mail. Please list your corrections by quoting the line number. If for any reason this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax; or scan the pages and return it by e-mail; or return it by post.
Please use this proof only for checking the typesetting, editing, completeness, and correctness of the text, and tables and figures. Significant changes to the article as accepted for publication will be considered at this stage only with permission from the Editor; and if granted, could delay publication. We will do everything possible to get your article published quickly and accurately; please let us have all your corrections within 48 hours.
It is important to ensure that all corrections be sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that we may proceed with the publication of your article as is if no response is received.
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via the offprint order form, which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at. You can also check our Author FAQs and/or contact Customer Support at
Highlights From The 8th Annual Community Oncology's Oncology Practice Summit»
|Dec 6 - 9|
|American Association for Cancer Research (AACR): International Conference on the Science of Cancer Health Disparities|
|Dec 7 - 10|
New Orleans, LA
|American Society of Hematology (ASH): Annual Meeting|
|Dec 10 - 14|
San Antonio, TX
|Cancer Therapy & Research Center (CTRC): San Antonio Breast Cancer Symposium (SABCS)|
|Dec 12 - 13|
|International Cardioncology Society (ICOS): Annual Conference Meeting|
|Jan 9 - 10|
|Breast - Gynecological International Cancer Society (BGICS): 6th BGICC Breast - Gynecological International Cancer Conference|
|Jan 16 - 18|
San Francisco, CA
|American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium|
|Jan 23 - 25|
San Francisco, CA
|Jonathan Wood & Associates: T-cell Lymphoma Forum|
|Jan 30 - Feb 1|
San Francisco, CA
|American Society of Clinical Oncology (ASCO): Genitourinary Cancers Symposium|
|Jan 30 - 31|
|European Organization for Research and Treatment of Cancer (EORTC): 1st Cancer Survivorship Summit|
|Feb 5 - 7|
|International Congress on Anti-Cancer Treatment (ICACT)|